Gut microbiota changes by an sglt2 inhibitor, luseogliflozin, alters metabolites compared with those in a low carbohydrate diet in db/db mice

HIGHLIGHTS

• who: Shinnosuke Hata and colleagues from the Department of Endocrinology and Metabolism, Graduate School of Medical Science, Kyoto Prefectural University of Medicine, Kyoto, Japan have published the research: Gut Microbiota Changes by an SGLT2 Inhibitor, Luseogliflozin, Alters Metabolites Compared with Those in a Low Carbohydrate Diet in db/db Mice, in the Journal: Nutrients 2022, 14, x FOR PEER REVIEW Enterobacteriaceae, of /2022/
• what: The aim of this study was to confirm the anti-sarcopenic effect of luseogliflozin on LCD, using db/db mice fed an equal weight dose diet of AIN93G with either 51 . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.